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Fragile X Syndrome (FXS) is the most common form of inherited intellectual disability, caused by
developmentally regulated inactivation of FMR1, leading to the absence of its encoded protein FMRP.
We have previously shown that undifferentiated Fragile X human Embryonic Stem Cells (FX-hESCs)
express FMRP, despite the presence of the full FMR1 mutation (4200 CGG repeats). We describe here,
for the ﬁrst time, in-vitro differentiation of FX-hESCs into neurons progressively inactivating FMR1.
Abnormal neurogenesis and aberrant gene expression were found already during early stages of
differentiation, leading to poor neuronal maturation and high gliogenic development. Human FX
neurons ﬁred action potentials but displayed poor spontaneous synaptic activity and lacked reactivity
to glutamate. Our dynamic FX-hESCs model can contribute to the understanding of the sequence of
developmental events taking place during neurogenesis and how they are altered in FXS individuals,
leading to intellectual disability. Furthermore, it may shed light over the striking phenotypic features
characterizing FXS in human.
& 2012 Elsevier Inc. All rights reserved.Introduction
Fragile X Syndrome (FXS) is the most common form of inherited
intellectual disability. It is an X-linked trait caused by silencing of
the FMR1 gene and the consequent absence of its protein, Fragile X
Mental Retardation Protein (FMRP) (Penagarikano et al.,
2007).FMR1 is inactivated due to a dynamic mutation caused by a
CGG-triplet repeat expansion in the 5’-untranslated region of the
gene (Verkerk et al., 1991). However, the CGG-expansion by itself is
not sufﬁcient to cause FMR1 inactivation, and in FXS individuals,
FMR1 is down-regulated gradually during embryonic development
(Sutcliffe et al., 1992; Wang et al., 2012). Indeed, chorionic villi
samples taken from FXS fetuses, lack FMRP only at week 12.5 of
pregnancy (Willemsen et al., 2002). Furthermore, in healthy fetuses
FMR1 expression is initially expressed in several tissues, but is
restricted to neurons later in development (Abitbol et al., 1993;
Bhakar et al., 2012), suggesting a role for FMRP in early neurogen-
esis. Therefore, the initial stages of brain development in both
healthy and FX-embryos take place in the presence of FMRP.
However, neurons are continuously generated and synapses are
still formed even at later stages of development when FMRP isll rights reserved.
, Racine IVF Unit, Lis
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).absent in FXS, leading to intellectual disability (Hagerman and
Stafstrom, 2009; Hagerman, 1987; Willemsen et al., 2004). There-
fore, studies of early neural development and its correlation with
FMR1 gradual inactivation may shed light on the pathophysiology
of FXS and the etiology of intellectual disability.
A number of FMR1 knock-out (KO) animal models have been
generated (D’Hulst and Kooy, 2009; den Broeder et al., 2009; Lim
et al., 2005; Mientjes et al., 2006; Wan et al., 2000), but they do not
express FMR1 even at early stage of development (Chen et al., 2010).
Human in-vitro models for studying FXS include post-mortem adult
neurons (Irwin et al., 2001), adult neural progenitors (Schwartz
et al., 2005), or fetal neural progenitor cells (Bhattacharyya et al.,
2008; Castren et al., 2005). Such cells show mild differences in their
morphology and gene expression from normal human controls
(Bhattacharyya et al., 2008), but signiﬁcant differences from their
fmr1/ mice counterparts (Castren, 2006; Castren et al., 2005).
Studies on human FX-dendritic spines are inconsistent with their
fmr1/ mice counterparts (Beckel-Mitchener and Greenough,
2004; Braun and Segal, 2000). Consequently, the phenotypic
abnormalities observed during FX neurogenesis vary among the
different FXS models available for research.
Human Embryonic Stem Cells (hESCs) are of great importance
in biology and medicine, due to their ability to grow indeﬁnitely in
culture, while maintaining their potential to differentiate into all
cell types in the human body (Reubinoff et al., 2000; Thomson
et al., 1998). In addition, hESCs can be used to study developmental
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research model currently exists. We have recently derived male
FX-hESC lines, carrying the naturally occurring full FXS mutation,
from Pre-implantation Genetic Diagnosis (PGD) affected blastocysts
(Eiges et al., 2007; Malcov et al., 2007). Our results demonstrated
that pluripotent FX-hESCs express FMR1, albeit full expansion of the
CGG-repeat region (Eiges et al., 2007). Furthermore, we have
demonstrated that FMR1 inactivation is developmentally regulated
in FX-hESCs, as it is in human FXS individuals during pregnancy.Fig. 1. Schematic representation of the in-vitro neural differentiation process. The pri
embryonic neurogenesis. Undifferentiated hESCs (Und) are derived from the inner c
suspension to form aggregates, corresponding to neuro-ectodermal cells (NE) present in
amount of neuro-ectoderm in these aggregates. They are then plated onto laminin-coa
neuro-epithelial cells. This stage recapitulates neural tube formation with a clear cen
developed NR are then detached and grown in suspension, allowing them to create neu
developing central nervous system (CNS) of the embryo. NS are then plated onto p
medium (NDM) and pro-neural factors, including BDNF, GDNF and NT-3. Approximate
long projections sprouting out from the attached NS. Fully developed neurons are obsRecently, human induced Pluripotent Stem Cell (hiPSC) lines were
generated from ﬁbroblasts of FXS individuals (Sheridan et al., 2011;
Urbach et al, 2010). Despite successful reprogramming of FX
somatic cells, FMR1 remained inactive and FMRP expression was
absent, even at the undifferentiated stage, resemblingfmr1/
models. These data highlight critical differences between hESCs
and hiPSCs in modeling FXS.
Given these considerations we here focus on the FX-hESC lines
we have recently derived, and exploit this unique cell system, toncipal steps of in-vitro neural differentiation are shown in correlation to normal
ell mass (ICM) of the blastocyst. Colonies of hESCs are detached and grown in
the gastrula. Treatment with NIM and noggin was meant to increase the relative
ted plates to allow the formation of neural tube-like rosettes (NR) enriched with
tral pseudo-lumen between concentrically elongated neuro-epithelial cells. Fully
rospheres (NS) enriched with neural progenitor cells, known to be present in the
oly-D-lysine/laminin-coated coverslips, supplemented with neural differentiation
ly one week following plating, it is possible to observe neuroblasts demonstrating
erved approximately 450 days following differentiation induction.
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leading to FXS. In the present study we show for the ﬁrst time
that directed differentiation of FX-hESCs into the neural lineage
induced down-regulation of FMR1 expression, coupled with
aberrant expression of key neural genes and phenotypic abnorm-
alities. This is the ﬁrst report on the successful generation of
active neurons from FX-hESCs, which are able to create neuronal
networks. The alterations observed during early stages of neuro-
genesis can explain the abnormalities observed at the end point of
the process, including low neurogenic potential and maturation
capability, as well as impaired neuronal functionality and poor
synaptogenesis. These key differences can probably be attributed
mainly to the neuro-developmentally regulated gradual silencing
of FMR1 characterizing both FXS and FX-hESCs.Materials and methods
Human Embryonic Stem Cells (hESCs)
The use of spare IVF-derived embryos diagnosed by Pre-
implantation Genetic Diagnosis (PGD) for the derivation of hESCs
was approved by the Israeli National Ethics Committee (7/04-043).
Three male FX-hESC lines were studied: HEFX1 (Ben-Yosef et al.,
2011; Eiges et al., 2007; Frumkin et al., 2010), SZ-FX6 (Ben-Yosef
et al., 2011) and Lis_FX6 (fully characterized in Fig. 3).In the current
study these three lines are entitled FX1, FX2 and FX3, respectively.
FX1 and FX3 were established at Tel-Aviv Sourasky Medical Center,
while FX2 was kindly provided by Dr. Rachel Eiges from Shaare
Zedek Medical Center. Three non-affected FMR1 hESC lines were
used as normal controls: HUES-13, HUES-16 and HUES-6 (Bock
et al., 2011; Cowan et al., 2004; Osafune et al., 2008), kindly
provided by Dr. Douglas Melton. HUES-13 and 16 are both classiﬁed
as highly neurogenic lines, while HUES-6 is a low neurogenic line.
Cells were cultured on mitomycin-C treated mouse embryonic
ﬁbroblasts in hESC medium. Characterization of hESCs included
expression of OCT4, NANOG, SSEA-3, SSEA-4 and TRA-1-60. Karyotype
analysis was performed as previously described (Eiges et al., 2007).
FMR1 CGG-expansion was analyzed by either Southern Blot as we
described previously (Eiges et al., 2007), or by FMR1 Sizing PCR Kit
(Abbott) which is currently used for diagnosing FXS (Fig. S1).
Differentiation potential was assessed by teratoma induction, as
previously described (Eiges et al., 2007). Teratoma sections were
stained with eosin and hematoxylin.
In-vitro neural differentiation
The in-vitro neural differentiation protocol used in this study
is based on Xia and Zhang (2009) and Zhang and Zhang (2010)
with slight modiﬁcations. These protocols, in which undifferen-
tiated hESCs are induced to differentiate into neurons, were
designed to mimic the different stages of neurogenesis. In general,
the process can be divided into early and late stages of neural
differentiation, as depicted in Fig. 1.
Early stages (day 0 to 30)
hESC colonies were enzymatically lifted (Collagenase IV, 1 mg/
ml) and grown in suspension to create ﬂoating Neuro-Ectoderm
aggregates (NE). NE aggregates were grown for 7 days: 4 days in
DMEM:F12 containing 20% knock-out serum replacement, 1%
glutamax, 1% insulin transferrin selenium, 1% non-essential
amino acids, 50 ng/ml primocin (InvivoGen) and 200 ng/ml nog-
gin; and 3 days in Neural Induction Medium (NIM) composed of
DMEM:F12 containing 1% N2, 0.5% B27 (w/o Vitamin A), 1%
glutamax, 1% non-essential amino acids, 50 ng/ml primocin,
20 ng/ml bFGF (R&D) and 200 ng/ml noggin. NE were plated ontolaminin (20 mg/ml, Sigma) coated polystyrene well plates (Grei-
ner), and cultured in NIM supplemented with 20 ng/ml bFGF,
either alone or with 200 ng/ml Shh (sonic hedgehog), until they
developed into neural tube-like rosettes (NR). NR were detached
by gentle pipetting and further grown in suspension (NIM
supplemented with 20 ng/ml bFGF) to create Neurospheres (NS).
Cells still attached to the plate were passaged and stable lines of
Neural Precursor Cells (NPCs) were derived.
Late stage
At day 30, NS were mechanically triturated, and plated on
glass coverslips (Thermo), coated with poly-D-lysine/laminin
(Sigma, at a ﬁnal concentration of 10 mg/ml and 20 mg/ml,
respectively). Plated NS were grown in Neural Differentiation
Medium (NDM) composed of Neurobasal containing 1% N2, 1%
B27 (w/o Vitamin A), 1% glutamax, 1% non-essential amino acids,
50 ng/ml primocin; supplemented with BDNF, GDNF and NT-3
(Peprotech, all at a ﬁnal concentration of 10 ng/ml). Following NS
ﬁnal plating, neuroblasts developed within one week to 10 days.
Full developed neurons and glia were observed 420 days post-
plating.
RNA puriﬁcation and qRT-PCR
RNA was extracted (RNeasy Mini Kit – Qiagen), and stored at
80 1C, containing RNAse Inhibitor (Roche). DNA decontamina-
tion was performed using DNAseI (Roche). RNA (100 ng) was
reversed transcribed with Super Script III RT-PCR kit (Invitrogen).
Quantitative Real Time PCR (qRT-PCR) was performed using SYBR
Green (ABgene). Cycling and analysis were performed using Rotor
Gene 6000 Series (Corbett) and its complementary analysis soft-
ware. The housekeeping gene GAPDH was used as a control for
DDCt analysis of results. All qRT-PCR assays included Non-
Template Control (NTC), non-human control cells (MEF) and adult
human-FXS white blood cells. Oligo-DNAs (custommade primers)
were purchased from Sigma–Aldrich, see Table S1.
Immunostaining
Cells were ﬁxated with Fixation Buffer (Sigma), incubated
overnight at 4 1C with primary antibodies in PBS containing
2.5% BSA (Sigma) and 0.5% Triton. Secondary antibodies included
sheep a-mouse Cy2-conjugated and goat a-rabbit Cy3- conju-
gated (Jackson Labs) for 1 h at RT. DAPI (Sigma) was used for
nuclear staining in all experiments. Immunostaining was visua-
lized in an Olympus IX51 Inverted Light Microscope or in a Zeiss
LSM 510 Confocal Laser Scanning Microscope. Images were
processed, including cropping of speciﬁc regions of interests,
using Olympus CellA or Zeiss LSM Image Browser software,
accordingly. For a complete list of all antibodies used see Table S2.
FACS analysis
FACS analysis of undifferentiated hESCs was performed using
AF-488 SSEA-3 and AF-647 TRA-1-60 antibodies (BioLegend), and
their respective isotype controls. Samples were analyzed using a
BD FACS Canto ﬂow cytometer (BD Biosciences).
Electrophysiological recordings
Neurons on glass coverslips were transferred to a recording
chamber in standard recording medium, containing (in mM): 10
HEPES, 4 KCl, 2 CaCl2, 1 MgCl2, 139 NaCl, 10 D-glucose
(340 mOsm, pH 7.4). Cells were patch-clamped with pipettes
containing (in mM) 136 K-gluconate, 10 KCl, 5 NaCl, 10 HEPES,
Fig. 2. Gene expression analysis of early neural differentiation. Relative transcript levels detected by qRT-PCR in HUES-13 (black circles), HUES-16 (black triangles), FX1
(white circles) and FX2 (white triangles), in 2 or 3 different experiments for each line; calculated as relative to GAPDH expression (DDCt) in the undifferentiated sample
(mean7s.e.m.). RNA samples extracted at four time-points along early neural differentiation: Und (undifferentiated, day 0), NE (neuro-ectoderm aggregates, day 7), NR
(neural rosettes, day 15–20) and NS (neurospheres, day 30). (A) FMR1, (B) Pluripotency markers: OCT4 and NANOG, (C) Early neural genes: SOX1, NOTCH1, PAX6 and NESTIN
and (D) Late neural genes: b-III-Tubulin and TAU (MAP-T).
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(pipette tip resistance was 5–8 MO). Action potentials were
evoked either by injecting depolarizing current pulses (current-clamp) or by depolarizing pulses (voltage-clamp). Membrane
potential was held at 60 mV. Spontaneous synaptic currents
were recorded continuously for up to 2 min in voltage clamp with
Fig. 3. Characterization of Lis_FX6 (FX3) hESC line. (A) Colony morphology of FX3 hESCs at passage 47. (B) Karyotype analysis by Giemsa staining. (C) Immunostaining
assays on undifferentiated colonies of FX3 hESC lines for the detection of SSEA-4 (green), FMRP (red), OCT4 (green) and TRA-1-60 (green). Nuclear staining in blue (DAPI).
(D) qRT-PCR of OCT4 (black) and NANOG (white) expression in undifferentiated hESCs (‘‘Und’’) and inactivation following 70 days of differentiation (‘‘Diff’’). (E) FACS
analysis reveals 89.4% positive cells for SSEA-3. (F) Analysis of FMR1 CGG repeat expansion, including the full mutation range (180-500 CGG repeats). Normal female and a
FX female served as controls. (G) Hematoxylin and eosin staining of FX3-derived teratoma sections, showing tissue structures corresponding to the three germ layers: (I)
glandular-like structures (ectoderm), (II) mesenchymal tissue (mesoderm) and epithelial polarized cells (ectoderm), (III) cartilage-like structure (mesoderm); and (IV)
intestine-like structure (endoderm).
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Fig. 4. Neural rosettes and neuroblasts development. (A) Neural rosettes (NR) from FX-hESC lines. Timing of NR development: mean number of days7s.e.m. following
plating of neuro-ectoderm aggregates, supplemented with 20 ng/ml bFGF only (I); or together with 200 ng/ml Shh (II). (B) Neuroblasts from FX-hESC lines. A neuroblasts
network developing from a single neurosphere 7 days following plating (I). Doublecortin (DCX) immunostaining (green) of neuroblasts (II). Timing of neuroblast
development: number of days (mean7s.e.m.) following neurosphere plating (III). (C) Neurite morphology analysis in neuroblasts, on phase images using the function for
arbitrary graphic measurement (from point to point) CellA complementary software – Olympus (I). Neurite length (II), neurite thickness close to the soma (III) and close to
the terminal end (IV). Each measurement was performed on at least 40 cells for each line. Values are given in mm (mean7s.e.m.). Statistical analysis: 1-way ANOVA.
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Fig. 5. Human FX neurons derived from Fragile X hESCs. (A) Representative pictures of fully developed neurons derived from hESCs. (I) Phase image of an in-vitro neuronal
network, (II&III) TUJ1 (b-III-Tubulin) staining (green), (IV) MAP2 (red) and Synaptophysin (green puncta), (V) MAP2 (red) and Synaptotagmin (green puncta), and (VI)
bright ﬁeld (left) and TAU staining (right, green) a single cell. Nuclear staining in blue (DAPI). (B) Representative images of neuronal networks derived from three FX-hESC
lines. Bright ﬁeld images of FX1 (I), FX2 (II) and FX3 (III). MAP2 staining (red) for the same lines (panels V and VI, respectively).
M. Telias et al. / Developmental Biology 374 (2013) 32–4538a 50 ms sampling rate. Glutamate was diluted in extracellular
recording solution and applied by pressure from a patch pipette.
Signals were ampliﬁed with a Multiclamp700B ampliﬁer and
recorded with Clampex 9.2 software (Axon Instruments). Data
were subjected to a 500-Hz low-pass ﬁlter and analyzed using
Clampﬁt-9 and SigmaPlot.Results
Early stages of in-vitro neural differentiation in FX-hESCs
In the ﬁrst part of this study we have analyzed the effects of
the early stages of neural differentiation (Fig. 1) on two FX-hESC
lines (FX1 and FX2), as compared to two control non-affected
FMR1 hESC lines (HUES-13 and HUES-16), by analyzing the
expression levels and patterns of several key neural genes, in
correlation with FMR1 expression (Fig. 2). The results demon-
strate that neural differentiation induced signiﬁcant and steadyup-regulation of FMR1 transcription in control lines (Fig. 2A).
Following 30 days of differentiation, control neurospheres (NS)
demonstrated a 3.5-fold increase in FMR1 transcription. In
contrast, neural differentiation of FX lines failed to induce any
increase in FMR1 expression. In a previous study we have already
demonstrated that FX1 teratoma-derived ﬁbroblasts show a 20-
fold decrease in FMR1 transcription levels, only after 43 months
of culture (Eiges et al., 2007). We therefore hypothesized that
even lack of up-regulation following directed neural differentia-
tion of FX cells could be critical for normal neurogenesis. In order
to conﬁrm this, we tested the expression pattern and levels of
several pluripotent and neural genes in the same model of in-
vitro neural differentiation. Our results show that the pluripo-
tency markers OCT4 and NANOG were down-regulated upon
induction of in-vitro neural differentiation, in both control and
FX cells (Fig. 2B). In contrast, the neural genes SOX1, NOTCH1 and
PAX6 showed aberrant or lower expression in FX1 and FX2, as
compared to control counterparts (Fig. 2C). Speciﬁcally, SOX1 and
PAX6 showed lack of activation in FX lines. NOTCH1 expression
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regulation followed by later increase as a result of enrichment
in neural precursor cells (NPCs) within the NS, as already shown
by others (Borghese et al., 2010). However, FX lines showed an
aberrant expression pattern of NOTCH1, with up-regulation at the
neuro-ectoderm (NE) stage and delayed down-regulation, prob-
ably linked to the inactivation of FMR1 in these cells. Nonetheless,
other early neural genes such as NESTIN (Fig. 2C), NEUROD1 and
MUSASHI (data not shown), did not show any signiﬁcant differences
in either expression levels or patterns, between FX and control cells.
Late neural genes such as b-III-Tubulin and TAU (MAP-T), which are
important for neuronal cytoskeleton formation, can be detected
already at early stages, such as neural rosettes (NR) and NS
(Fig. 2D). Both genes were signiﬁcantly up-regulated in control
lines (especially in NS) as expected, but were under-expressed in FX
lines in correlation with FMR1 lack of up-regulation. In summary,
our results show that, in control hESCs FMR1 is up-regulated during
neural differentiation, correlating with normal neural gene expres-
sion. On the other hand, lack of FMR1 up-regulation in FX lines was
concomitant with mis-regulation of key neural genes. These ﬁnd-
ings were conﬁrmed at the protein level by immunostaining assays
performed on FX as compared to control NR (Fig. S2 and Table S3).
Altogether these results suggest that FMR1 may play a substantial
role in neurogenesis induction, already at early stages.
Neural rosettes and neuroblast development in FX-hESCs
We have recently derived a new male Fragile X human Embryo-
nic Stem Cell (FX-hESC) line from another PGD patient, entitled
Lis_FX6 and named ‘‘FX3’’ in the current study. Full characterization
of this new line is shown in Fig. 3. Encouraged by our preliminary
results showing abnormal neural gene expression, and following
derivation of FX3, we expanded our study to include three FX-hESC
lines (FX1, FX2, FX3) and three control lines. Control lines were
chosen according to their neurogenic potential: two lines (HUES-13
and HUES-16) are highly neurogenic, and one (HUES-6) is poorly
neurogenic (Bock et al., 2011; Osafune et al., 2008). Since FX lines
produced NR, albeit under-expression of early neural genes, it was
interesting to further analyze structural and phenotypic differences
during neurogenesis between FX and control lines. NR developed
from both FX and control hESC lines displaying the expected typical
morphology (Wilson and Stice, 2006), with a clear central pseudo-
lumen surrounded by columnar neuro-epithelium in a circular
monolayer structure. However, FX-NR developed signiﬁcantly
slower than control NR (Fig. 4A(I); po0.05). Addition of the puriﬁed
neural growth factor Sonic Hedgehog (Shh, 200 ng/ml), known to
induce neural tube formation (Christian, 2000), rescued the delay to
a non-signiﬁcant difference in timing of NR development between
FX and controls (Fig. 4A(II); p40.05).
Detachment of NR produced NS. Following NS plating onto PDL/
Laminin-coated coverslips, neuroblasts were produced, positively
stained for Doublecortin (DCX, Fig. 4B). Neuroblasts developed very
early in HUES-13, which was signiﬁcantly faster than the two other
control lines and the three FX lines (Fig. 4B(III)). This is probably
related to the intrinsic characteristics of HUES-13 as high neuro-
genic, and unrelated to FMR1 expression. Neuroblasts protruded
from the attached NS as bipolar cells with a small nucleus usually
with two long non-branched neurites that could be measured and
compared among the different lines using microscopic imaging and
a specialized software (Fig. 4C(I)). Neurite length was signiﬁcantly
longer in HUES-16 and HUES-6 neuroblasts, but similar between
HUES-13 and all three FX lines (Fig. 4C(II)). Neurite thickness
close to the soma was signiﬁcantly increased in HUES-13 and
signiﬁcantly decreased in FX3, but non-signiﬁcantly different
among the rest of the lines (Fig. 4C(III)). We have also found that
neurite thickness at its terminal end was similar among all lines,besides FX3 (Fig. 4C(IV)). Taken together, these differences cannot
account for a role of FMR1 in neurite formation and elongation,
contradicting results published using the drosophila dfxr/ model
(Morales et al., 2002) and the murine fmr1/ model (Comery et al.,
1997; Guo et al., 2011b; Irwin et al., 2000; Nimchinsky et al., 2001).
Biased neuron to glia ratio in FX cells is correlated to FMR1
expression
During ﬁnal stages of neural differentiation, at 20 to 30 days
after NS plating (50 to 60 days from differentiation induction), fully
developed neurons were obtained from all control lines (Fig. 5).
These in-vitro hESCs-derived neuronal networks (Fig. 5A(I)) were
positively stained for TUJ1, MAP2, TAU and NeuN (Figs. 5A and 6A).
These cells also expressed synaptic proteins, including synaptophy-
sin and synaptotagmin (Fig. 5A(III and IV)). Similarly, all three FX
lines produced complex neuronal networks, although at lower
yield, and these neurons could be kept in culture for several weeks
(Fig. 5B). Following this ﬁnal stage of neuronal differentiation, we
examined FMRP expression in 460 days old neurons (MAP2þ and
NeuNþ) and glial cells (GFAPþ), developed from both control and
FX lines. Control neurons expressed FMRP, similar to what is known
from healthy individuals (Fig. 6A(I) and (II), upper panels). How-
ever, FX neurons developed in-vitro from FX-hESCs, lacked FMRP
(Fig. 6A(I) and (II); lower panels). Interestingly, both control and FX
glial cells (GFAPþ) expressed FMRP (Fig. 6A(III)). Inactivation of
FMR1 in late stages of neural differentiation of FX lines was
conﬁrmed by qRT-PCR in FX NPCs and in mechanically isolated
FX neurons (Fig. 6A(V)). These results indicate that: (i) FX-hESCs can
successfully differentiate into neurons in-vitro; (ii) this model
mimics the process of FMR1 inactivation as it occurs during
embryogenesis of FXS fetuses, with expression of FMR1 at early
stages and it is developmentally regulated by silencing until
complete inactivation in FX neurons.
In order to compare the neurogenic potential of FX cells to
their control counterparts, we carried out double immunostaining
assays for MAP2/GFAP on these cultures (Fig. S3). Quantiﬁcation
of these assays revealed that neuronal yield (MAP2þ cells) of
control lines corresponded their neurogenic potential (Bock et al.,
2011; Osafune et al., 2008), with the high neurogenic lines HUES-
13 and HUES-16 producing 470% neurons and the low neuro-
genic line HUES-6 producing 25% neurons (Fig. 6B(I)).
In contrast, all FX lines produced low neuronal yields, similar to
HUES-6. Since HUES-6 actively expresses FMR1/FMRP, similar to the
other two control lines, we conclude that low neurogenic potential
of FX lines is only partially caused by lack of FMRP. Quantiﬁcation
of GFAPþ cells revealed a very low production of glia (o15%) in all
three control lines. In contrast, all three FX lines produced 470%
GFAPþ cells (Fig. 6B(II)). In all control lines, there were cells (27%
to 65%) which did not stain positive for either MAP2 or GFAP
(double negative) (see Table S4). This double negative population
was signiﬁcantly reduced in FX1 (5%) and FX3 (11%). Moreover,
in FX2 line 19% of cells were stained positive for both MAP2 and
GFAP (double positive; Table S4). Since GFAPþ cells in FX1, FX2 and
FX3 are still FMRPþ (see Fig. 6A(III)), we conclude that this bias of
FX cells towards the glial lineage is linked to the aberrant
neurogenesis of FX lines, observed already at early stages, due to
abnormal regulation of FMR1.
Functional analysis of human FX neurons
In order to increase FX neuronal yield, we seeded the FX NS at
a higher density (two- to three-fold higher than standard proto-
col). Indeed, in these conditions, the yield of FX neuronal cultures
increased, allowing us to perform extensive electrophysiological
analysis into their functional properties. Neurons obtained from
Fig. 6. Late neural development of FX and control hESCs. (A) Representative pictures of double immunostaining assays (repeated in all lines). (I) FMRP (green, monoclonal)
and MAP2 (red): co-localization in HUES-13 (yellow), but not in FX1. (II) NeuN (green) and FMRP (red, polyclonal): co-localization in HUES-13 (yellow), but not in FX3. (III)
FMRP (red) co-localized with GFAP (green) in both HUES-16 and FX3 cells. (IV) FMR1 relative transcript levels analyzed by qRT-PCR in control and FX neural precursor cells
(NPCs, left) and in isolated neurons (right). Each bar represents the level of transcription relative to its undifferentiated stage. (B) Quantiﬁcation of MAP2 (I) or GFAP (II)
stained cells, in at least 5 ﬁelds including at least 30 cells per ﬁeld, for each line studied, for each experiment carried out. Values correspond to average percentage (%) of
MAP2 or GFAP positive cells relative to total DAPI staining. Statistical analysis: 1-way ANOVA.
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analysis, in order to assess both intrinsic and synaptic neuronal
properties. Voltage clamp recordings did not reveal signiﬁcant
differences between control and FX neurons; as both expressedinward Naþ currents, and two types of outward Kþ currents, a
transient and a sustained one (Fig. S4). Current clamp recordings
revealed that passive properties (membrane time constant, rest-
ing potential and input resistance) are similar in control as
Fig. 7. Patch clamp recordings from wt and FX neurons. (A) Representative illustrations of action potentials recorded in current clamp mode. Holding potential was
60 mV. Cells were subjected to 14 consecutive 10 pA current pulses (bottom), and their voltage deﬂection was recorded (top). Insets (taken from the I–V illustrations):
ﬁrst action potential in response to the depolarizing current pulse. Arrows in inserts show the two points for measurement of Spike Rise Time (see Table 1). (B) Representative
traces of spontaneous synaptic currents recorded from patch-clamped neurons in voltage clamp mode (left: HUES-13, cell #5 in Table 1B; and right: FX3, cell #1 in Table 1B).
(C) Left: representative traces of glutamate response of patch-clamped neurons from HUES-13 (blue) and FX3 (red) at 40mV and þ40 mV. Right: I–V curve of glutamate
response from 60 to þ60 mV (mean7s.e.m.), for HUES-13 (blue, 2 mM glutamate, n¼10) and FX3 (red, 2 mM glutamate, n¼8; 200 mM glutamate, n¼2; total n¼10).
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potential properties demonstrated signiﬁcant differences
between FX and control in spike rise time and duration, andin the maximum number of spikes per depolarization (Table 1).
The threshold for evoking an action potential was not signiﬁcantly
different, but FX3 neurons expressed a much slower action
Table 1
Summary of data obtained from current clamp recordings. Summary of results
obtained from recordings in current clamp modality in 20 HUES-13 neurons and
20 FX3 neurons. t – time constant of decay obtained from exponential standard
ﬁtting curve f(t)¼SAiet/tiþC. Em – Resting membrane potential. Rin – Input
resistance. Spike amplitude values above 0 mV. Spike rise time was measured in
ms, as depicted by black arrows in the insets of Fig. 7A. Values in the table are
given as mean7s.e.m. P values obtained by t-test.
Current clamp HUES-13 (n¼20) FX3 (n¼20) p value
s (msec) 47.3075.98 42.9273.33 0.53
Em (mV) 60.1871.63 63.5272.24 0.51
Rin (MO) 732.63786.33 699.14752.50 0.74
Max. spikes per depolarization 2.7570.43 1.0070.00 o0.001
Spike threshold (mV) 24.7871.70 19.7571.97 0.10
Spike amplitude (mV) 25.6472.86 25.0572.48 0.88
Spike rise time (ms) 27.7973.74 13.3671.06 o0.001
Spike duration (ms) 2.8370.25 3.8370.28 0.02
After potential (mV) 4.5172.90 4.4971.70 0.26
Table 2
Summary of recorded spontaneous synaptic currents in voltage clamp. HUES-13
and FX3 neurons were analyzed in voltage clamp modality for their capability of
spontaneously generating synaptic currents (5 out of 10 HUES-13 neurons and
2 out of 10 FX3 neurons). Measured parameters in each cell included: total
number of Synaptic Currents observed during 2 min of continuous recording, Rise
Time, Amplitude and t (time constant of decay, obtained from exponential
standard ﬁtting curve f(t)¼SAie t/tiþC). All values in the table are given as
mean7s.e.m.
Synaptic
currents
Cell
#
Synaptic
currents
Rise time
(msec)
Amplitude
(pA)
s
(ms)
HUES-13
(5 out of 10)
1 14 2.4970.20 19.7771.29 5.9371.84
2 7 1.6470.07 21.0673.34 3.4370.55
3 10 1.6770.15 26.0173.05 2.0270.22
4 50 2.0370.05 98.1971.27 2.3270.04
5 2 2.2570.25 114.80736.34 2.5770.08
FX3
(2 out of 10)
1 20 1.2370.07 21.6270.42 1.1870.14
2 12 1.5770.37 16.1070.92 0.9470.45
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as was in HUES-13 neurons (see Fig. 7A, insets; and Table 1). In
voltage clamp recording mode we analyzed the occurrence and
characteristics of spontaneous synaptic currents (Fig. 7B). In 5 out
of 10 control neurons tested, spontaneous synaptic currents were
detected. In contrast, only 2 of 10 FX3 neurons expressed synaptic
currents. FX3 synaptic currents displayed lower values of rise time
and time constant of decay (t), but almost similar values of
amplitude, as compared to HUES-13 (Table 2). Finally, we assessed
whether these hESCs-derived neurons were responsive to gluta-
mate. Representative traces show that control neurons responded
to glutamate, at holding potential of 40 mV by a reversible
inward current, and at holding potential of þ40 mV by an outward
current (Fig. 7C, blue). I–V curve of glutamate responses shows that
in HUES-13 neurons the response to glutamate reversed around
0 mV. Interestingly, even the two FX3 neurons that expressed
synaptic currents were unresponsive to glutamate, at any voltage
tested, even with glutamate concentrations that were 100-fold
higher than those used for control (Fig. 7C, red). It is also important
to mention that all FX3 neurons tested for glutamate responses
were found to be electrically excitable (by both current and voltage
clamp), before and after glutamate application. These results
demonstrate that FX-hESC cells can differentiate into viable neu-
rons, which display passive properties similar to control cells.
However, FX3 neurons hardly developed functional synaptic
connections.Discussion
In the present study we have used a dynamic Fragile X human
Embryonic Stem Cells (FX-hESCs) model in order to analyze the
temporal sequence of events during neural differentiation. This is
the only research model of Fragile X Syndrome (FXS) that
recapitulates neurogenesis in a human system in which FMR1 is
expressed at early embryogenesis and is developmentally inacti-
vated, similar to the process occurring in human FX fetuses. The
results of the current study show that direct differentiation into
the neural lineage induces gradual down-regulation of FMR1
expression in FX-hESCs, as opposed to the FMR1 up-regulation
characterizing this stage in control counterparts. Early stages of
FX neurogenesis show aberrant expression patterns of key neural
genes and developmental abnormalities in neural rosettes (NR).
During ﬁnal stages of neural differentiation, a signiﬁcant shift
towards the glial lineage was observed in FX lines, in correlation
with FMR1 expression. Albeit the abnormalities observed in FX
cells during the process, and their low neuronal efﬁciency, these
are the ﬁrst human FX pluripotent cells that developed into
electrophysiologically active neurons. Extensive functional analy-
sis of these neurons shows that FMR1 down-regulation leads to
the formation of neurons with poor synaptic capability and lack of
response to glutamate.
FMR1 expression was already shown to be restricted mainly to
the central nervous system during human embryogenesis
(Abitbol et al., 1993), and its absence was shown to be coupled
with abnormal neurogenesis (Castren, 2006; D’Hulst and Kooy,
2009). However, the spatiotemporal sequence of events linking
between gradual down-regulation of FMR1 and abnormal neuro-
genesis are difﬁcult to observe in KO animal models, since FMR1
expression is absent in these animals even at early stages of
development. We have previously demonstrated that FX-hESCs
recapitulate in-vivo FXS pathology, by expressing in-vitro FMR1/
FMRP at the undifferentiated pluripotent stage, which is gradually
down-regulated along spontaneous differentiation (Eiges et al.,
2007). We show here that directed differentiation into the neural
lineage is characterized by lack of FMR1 up-regulation, concomi-
tantly with an aberrant expression pattern of SOX1, PAX6 and
NOTCH1, genes that have been found to be responsible for
inducing neurogenesis (Borghese et al., 2010; Chambers et al.,
2009; Georgala et al., 2011; Yan et al., 2009). In contrast, other
neural genes such as NESTIN showed normal activation in FX-
hESC lines. In accordance, neural progenitors differentiated from
FX human induced Pluripotent Stem Cells (hiPSCs) showed a
signiﬁcant reduced expression of SOX1, but a normal expression
of NESTIN (Sheridan et al., 2011). In human FX neural progenitors,
harvested from a FXS fetus (with inactive FMR1), neural differ-
entiation resulted in the abnormal expression of several neuro-
developmental genes (Bhattacharyya et al., 2008). Since FMRP is
an mRNA-binding protein controlling levels of translation, subtle
dosage alterations could be responsible for important genetic
mis-regulation.
In the present study, we show that aberrant expression of
SOX1 and NOTCH1 in FX lines was observed in parallel with a
signiﬁcant delay in FX neural rosettes (NR) development. This
delay was rescued by addition of soluble sonic hedgehog (Shh), a
morphogen which plays a key role in regulation of organogenesis,
including brain development. It is tempting to speculate that lack
of FMR1 up-regulation in FX lines is probably sufﬁcient to induce
delayed NR formation. Rescue of NR formation by Shh, as well as
aberrant expression of SOX1 and NOTCH1 in the FX cells, both
suggest that FMR1 is probably involved in the Wnt signaling
pathway, affecting several aspects of neural differentiation
(Christian, 2000; Guo et al., 2011b; Kormish et al., 2010; Luo
et al., 2010; Patapoutian and Reichardt, 2000; Shih et al., 2010)
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FMR1/FMRP with members of the Wnt signaling pathway is
critical for adult neurogenesis in the murine hippocampus (Guo
et al., 2011b; Luo et al., 2010).The current study further demon-
strates such a link, between FMRP and Wnt, at early stages of
neural development.
FX neuroblasts developed neurites displaying morphological
traits that did not differ signiﬁcantly from controls. The subtle
variations, observed in the average neurite length and thickness,
do not account for a signiﬁcant and consistent impairment in
neurite formation during neuroblast development of FX-hESC
lines. Although at this stage FMR1 is already down-regulated in
FX cells, it is not completely inactivated. These results are in
contrast to the studies performed in FMR1 KO animals demon-
strating shorter and thicker dendritic spines in FX neurites
(Bianco et al., 2010; Comery et al., 1997; Guo et al., 2011a;
Irwin et al., 2000; Morales et al., 2002; Nimchinsky et al., 2001).
However, these alterations are probably due to the lack of FMRP
in KO animals at every neuro-developmental stage, resulting in a
phenotype that is much more detrimental than that of human FXS
individuals that express FMRP at early stages of neurogenesis.
Furthermore, studies performed on FX human neural progenitor
cells (FX-hNPCs), have shown contradicting results: a decrease in
FX-neurite length in one study (Castren et al., 2005), and no
differences in neurite morphology between FX and controls, in
another study (Bhattacharyya et al., 2008). Irwin et al. (2000,
2001) have shown that in adult FX human brain samples,
dendritic spines display abnormal morphology. However, this is
probably due to the effects FMRP absence in adult neural stem
cells (Luo et al., 2010), rather than abnormal development during
the embryonic period. Altogether, these results suggest that in
human, FMRP role in neurite formation is probably less critical
than that observed in KO animal models.
At late stages of neurogenesis we demonstrated low neuro-
genic potential of FX-hESC lines, concomitant with absence of
FMRP in FX neurons expressing MAP2 and NeuN. In the same
cultures, FX lines showed a strong bias towards differentiation
into GFAP expressing cells. These GFAP positive cells still express
FMRP, albeit originating from the same full mutated FX-hESC
lines. This can be explained either by a higher gliogenic potential
of the FX lines, or by impaired maturation, which prevents NPCs
expressing GFAP to mature into neurons (Guo et al., 2011a;
Kazanis and ffrench-Constant, 2011). A same GFAP bias was
observed during neurogenesis of fetal FX-hNPCs, fmr1/ murine
adult and embryonic neural stem cells, as well as in FX-hiPSCs
(Castren, 2006; Castren et al., 2005; Luo et al., 2010; Sheridan
et al., 2011). However, the FX-hESCs model is the only one able to
show that although FMRP is inactive in neurons (i.e., MAP2þ ,
NeuNþ) GFAPþ cells still express FMRP. Indeed, an active role for
FMRP was suggested in the astrocytic lineage (Pacey and Doering,
2007). However, this study also found cells co-expressing GFAP
and b-III-Tubulin, interpreted as a mixed subpopulation of
uncommitted glial and neural precursors. Similarly, we have also
found a subpopulation of cells co-expressing both MAP2 and
GFAP, suggesting that, at least in part, the bias towards GFAP
over-expression in FX lines represents lack of neural maturity.
The low efﬁciency in MAP2þ cells production observed in all
three FX lines resembles that of the control HUES-6, which is
known to have inherent low neurogenic potential, resulting in
both low neural and glial yield (Bock et al., 2011). However, each
FX-hESC line was originated from a different unrelated blastocyst.
It is possible to conclude that all three lines, independently, are
inherently low neurogenic (similar to HUES-6), but this conclu-
sion would not take into account the strong FX-related GFAP-
expression bias and the fact that in all three FX lines, MAP2þ cells
were FMRP-, but GFAPþ cells were FMRPþ . Taken together, thesedata suggest that FMR1 down-regulation and consequent FMRP
absence result in a delayed and reduced maturation of neural
precursors into the neuronal lineage. Under in-vitro conditions,
this phenomenon leads to an over-expression of GFAP, indicating
both a lack of maturation in some of the cells, and a shift in cell
fate in others.
The functional analysis of the derived FX neurons demon-
strates poor synaptic capability and lack of response to glutamate,
despite normal intrinsic properties. The harsh effect of FMRP
absence on synaptogenesis or synaptic maintenance could be
linked to the in-vitro process that seems to accelerate FMR1
down-regulation. It is possible that in-vitro down-regulation of
FMR1 during neural differentiation of FX-hESCs is faster than the
human in-vivo process. Therefore, it is tempting to speculate that
in human FX-fetuses FMRP is completely absent only after the
glutamate-dependent synaptic machinery is established. We
suggest that in-vitro neural differentiation of FX-hESCs may
accelerate the process of FMR1 down-regulation, causing a grave
impairment in synaptogenesis, whereas in-vivo this process is
probably slower, resulting in less severe effects. These aspects of
correlation between FMRP timing of under-expression and synap-
togenesis are hard to study in humans, because of limited
biological material (Bhattacharyya et al., 2008; Castren et al.,
2005) and the non-dynamic nature of hiPSCs (Urbach et al., 2010).
FX-hESCs offer a platform for further understanding of the
relationship between FMRP and synaptogenesis. Recently, three
studies were published in which FXS was ameliorated, following
treatment with metabotropic glutamate receptors antagonists
(Michalon et al., 2012; Thomas et al., 2012; Vinueza Veloz et al.,
2012). However, in all three studies, the suggested drugs were
examined on fmr1 / mouse models. The differences in FX
neurogenesis between KO animals and the FX-hESCs shown here,
suggest that a well-based human drug-screening model is needed
for ﬁnding a suitable therapy for the amelioration of early FXS
symptoms and the improvement of cognitive functions.
In conclusion, the FX-hESC model can recapitulate in-vitro,
many of the pathological events that take place during FXS
embryonic and fetal neurogenesis, providing tools for the under-
standing of aberrant neural differentiation at a molecular level
and in a spatiotemporal sequential paradigm. This model enables
the tracking of neural impairments associated with the absence of
FMRP during all stages of neural differentiation, and may also
guide the search for new therapeutic strategies that could
counteract inherited FXS related intellectual disability.Acknowledgments
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